Drug Manufacturers - Specialty & Generic
Compare Stocks
5 / 10Stock Comparison
AKAN vs DBVT vs ALKS vs TLRY vs CGC
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
Biotechnology
Drug Manufacturers - Specialty & Generic
Drug Manufacturers - Specialty & Generic
AKAN vs DBVT vs ALKS vs TLRY vs CGC — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology | Biotechnology | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
| Market Cap | $874K | $1690.08T | $5.83B | $648M | $119M |
| Revenue (TTM) | $2M | $0.00 | $1.56B | $1.17B | $294M |
| Net Income (TTM) | $-31M | $-168M | $153M | $-2.95B | $-327M |
| Gross Margin | -43.7% | — | 65.4% | 28.0% | 22.8% |
| Operating Margin | -6.3% | — | 12.3% | -266.0% | -24.1% |
| Forward P/E | — | — | 24.5x | — | — |
| Total Debt | $353K | $22M | $70M | $451M | $348M |
| Cash & Equiv. | $4M | $194M | $1.12B | $304M | $114M |
AKAN vs DBVT vs ALKS vs TLRY vs CGC — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Mar 22 | May 26 | Return |
|---|---|---|---|
| Akanda Corp. (AKAN) | 100 | 0.0 | -100.0% |
| DBV Technologies S.… (DBVT) | 100 | 124.1 | +24.1% |
| Alkermes plc (ALKS) | 100 | 133.0 | +33.0% |
| Tilray Brands, Inc. (TLRY) | 100 | 71.6 | -28.4% |
| Canopy Growth Corpo… (CGC) | 100 | 1.5 | -98.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: AKAN vs DBVT vs ALKS vs TLRY vs CGC
Each card shows where this stock fits in a portfolio — not just who wins on paper.
AKAN plays a supporting role in this comparison — it may shine differently against other peers.
DBVT is the clearest fit if your priority is income & stability.
- Dividend streak 0 yrs, beta 1.26
ALKS carries the broadest edge in this set and is the clearest fit for long-term compounding and sleep-well-at-night.
- -12.0% 10Y total return vs TLRY's -75.2%
- Lower volatility, beta 1.00, Low D/E 3.8%, current ratio 3.55x
- Beta 1.00, current ratio 3.55x
- 9.8% margin vs AKAN's -19.6%
TLRY is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 4.8%, EPS growth -6.5%, 3Y rev CAGR 12.5%
- 4.8% revenue growth vs DBVT's -100.0%
- +11.6% vs AKAN's -62.5%
Among these 5 stocks, CGC doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 4.8% revenue growth vs DBVT's -100.0% | |
| Quality / Margins | 9.8% margin vs AKAN's -19.6% | |
| Stability / Safety | Beta 1.00 vs TLRY's 2.04, lower leverage | |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | +11.6% vs AKAN's -62.5% | |
| Efficiency (ROA) | 5.4% ROA vs AKAN's -380.2%, ROIC 18.9% vs -7.5% |
AKAN vs DBVT vs ALKS vs TLRY vs CGC — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
AKAN vs DBVT vs ALKS vs TLRY vs CGC — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ALKS leads in 3 of 6 categories
TLRY leads 1 • AKAN leads 0 • DBVT leads 0 • CGC leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS and DBVT operate at a comparable scale, with $1.6B and $0 in trailing revenue. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to AKAN's -19.6%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $0 | $1.6B | $1.2B | $294M |
| EBITDAEarnings before interest/tax | -$8M | -$112M | $212M | -$3.0B | -$32M |
| Net IncomeAfter-tax profit | -$31M | -$168M | $153M | -$2.9B | -$327M |
| Free Cash FlowCash after capex | -$7M | -$151M | $392M | -$94M | -$86M |
| Gross MarginGross profit ÷ Revenue | -43.7% | — | +65.4% | +28.0% | +22.8% |
| Operating MarginEBIT ÷ Revenue | -6.3% | — | +12.3% | -2.7% | -24.1% |
| Net MarginNet income ÷ Revenue | -19.6% | — | +9.8% | -2.5% | -111.0% |
| FCF MarginFCF ÷ Revenue | -4.4% | — | +25.1% | -8.1% | -29.3% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — | +28.2% | +3.0% | +20.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +88.4% | +91.5% | -4.1% | +70.7% | +83.8% |
Valuation Metrics
Evenly matched — AKAN and DBVT and TLRY each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $873,882 | $1690.08T | $5.8B | $648M | $119M |
| Enterprise ValueMkt cap + debt − cash | -$3M | $1690.08T | $4.8B | $795M | $291M |
| Trailing P/EPrice ÷ TTM EPS | -0.10x | -0.75x | 24.47x | -0.16x | -0.27x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | 17.01x | — | — |
| Price / SalesMarket cap ÷ Revenue | 1.04x | — | 3.95x | 0.57x | 0.61x |
| Price / BookPrice ÷ Book value/share | 0.11x | 0.65x | 3.25x | 0.24x | 0.33x |
| Price / FCFMarket cap ÷ FCF | — | — | 12.14x | — | — |
Profitability & Efficiency
ALKS leads this category, winning 8 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-15 for AKAN. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to CGC's 0.72x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs TLRY's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -15.1% | -130.2% | +8.8% | -136.5% | -43.1% |
| ROA (TTM)Return on assets | -3.8% | -89.0% | +5.4% | -100.6% | -29.5% |
| ROICReturn on invested capital | -7.5% | — | +18.9% | -66.2% | -10.2% |
| ROCEReturn on capital employed | -3.0% | -145.7% | +14.2% | -78.1% | -12.4% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 7 | 4 | 5 |
| Debt / EquityFinancial leverage | 0.08x | 0.13x | 0.04x | 0.22x | 0.72x |
| Net DebtTotal debt minus cash | -$3M | -$172M | -$1.0B | $147M | $235M |
| Cash & Equiv.Liquid assets | $4M | $194M | $1.1B | $304M | $114M |
| Total DebtShort + long-term debt | $352,814 | $22M | $70M | $451M | $348M |
| Interest CoverageEBIT ÷ Interest expense | -47.93x | -189.82x | 32.30x | -89.43x | -7.79x |
Total Returns (Dividends Reinvested)
TLRY leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,165 today (with dividends reinvested), compared to $1 for AKAN. Over the past 12 months, TLRY leads with a +1157.1% total return vs AKAN's -62.5%. The 3-year compound annual growth rate (CAGR) favors TLRY at 26.0% vs AKAN's -82.5% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +174.4% | +3.6% | +23.8% | -42.8% | -6.7% |
| 1-Year ReturnPast 12 months | -62.5% | +100.5% | +15.2% | +1157.1% | -17.2% |
| 3-Year ReturnCumulative with dividends | -99.5% | +18.1% | +13.2% | +100.0% | -91.6% |
| 5-Year ReturnCumulative with dividends | -100.0% | -68.3% | +61.7% | -63.0% | -99.5% |
| 10-Year ReturnCumulative with dividends | -100.0% | -87.1% | -12.0% | -75.2% | -94.4% |
| CAGR (3Y)Annualised 3-year return | -82.5% | +5.7% | +4.2% | +26.0% | -56.2% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.00 beta — it tends to amplify market swings less than TLRY's 2.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 95.6% from its 52-week high vs AKAN's 14.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.46x | 1.26x | 1.00x | 2.04x | 1.95x |
| 52-Week HighHighest price in past year | $185.80 | $26.18 | $36.60 | $15.70 | $2.38 |
| 52-Week LowLowest price in past year | $1.41 | $7.53 | $25.17 | $0.35 | $0.84 |
| % of 52W HighCurrent price vs 52-week peak | +14.5% | +75.3% | +95.6% | +35.4% | +46.6% |
| RSI (14)Momentum oscillator 0–100 | 64.7 | 47.4 | 60.5 | 36.8 | 51.1 |
| Avg Volume (50D)Average daily shares traded | 2.7M | 252K | 2.2M | 4.7M | 10.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: DBVT as "Buy", ALKS as "Buy", TLRY as "Hold", CGC as "Hold". Consensus price targets imply 1203.6% upside for CGC (target: $14) vs 31.5% for ALKS (target: $46).
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Buy | Hold | Hold |
| Price TargetConsensus 12-month target | — | $46.33 | $46.00 | $10.00 | $14.47 |
| # AnalystsCovering analysts | — | 15 | 28 | 20 | 26 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.5% | 0.0% | 0.0% |
ALKS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TLRY leads in 1 (Total Returns). 1 tied.
AKAN vs DBVT vs ALKS vs TLRY vs CGC: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is AKAN or DBVT or ALKS or TLRY or CGC a better buy right now?
For growth investors, Tilray Brands, Inc.
(TLRY) is the stronger pick with 4. 8% revenue growth year-over-year, versus -61. 3% for Akanda Corp. (AKAN). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AKAN or DBVT or ALKS or TLRY or CGC?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.
7%, compared to -100. 0% for Akanda Corp. (AKAN). Over 10 years, the gap is even starker: ALKS returned -12. 0% versus AKAN's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AKAN or DBVT or ALKS or TLRY or CGC?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
00β versus Tilray Brands, Inc. 's 2. 04β — meaning TLRY is approximately 104% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 72% for Canopy Growth Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — AKAN or DBVT or ALKS or TLRY or CGC?
By revenue growth (latest reported year), Tilray Brands, Inc.
(TLRY) is pulling ahead at 4. 8% versus -61. 3% for Akanda Corp. (AKAN). On earnings-per-share growth, the picture is similar: Akanda Corp. grew EPS 100. 0% year-over-year, compared to -651. 7% for Tilray Brands, Inc.. Over a 3-year CAGR, AKAN leads at 172. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — AKAN or DBVT or ALKS or TLRY or CGC?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -489. 6% for Akanda Corp. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -523. 8% for AKAN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — AKAN or DBVT or ALKS or TLRY or CGC?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is AKAN or DBVT or ALKS or TLRY or CGC better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
00)). Tilray Brands, Inc. (TLRY) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -12. 0%, TLRY: -75. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between AKAN and DBVT and ALKS and TLRY and CGC?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.